1. The Novel Tablet

2. The Contributors Commercialization Plan by: Commercialization Plan by: Sarah Fister Sarah Fister Merchandising Management Merchandising Management Jimmy Neyhart Jimmy Neyhart Business Administration Business Administration Carly Stoughton Carly Stoughton Computer Science Computer Science Research contributors: Dr. Jim Ayres Inventor, OSU College of Pharmacy Dr. Mark Christensen Inventor, OSU College of Pharmacy Bill Newman Mentor, Hewlett- Packard Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

3. An effective, long-lasting drug delivery system does not exist Customers are inconvenienced by taking multiple doses throughout the day Current drug delivery systems are inconsistent in their dosage administration The Problem Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

4. The Solution “Mean fever reductions and mean acetaminophen concentration in saliva. Observed temperature and mean acetaminophen concentration over time were observed in different groups of children. Open circles, mean acetaminophen concentration in saliva of children who absorb acetaminophen slowly…closed squares mean fever reduction” – U.S. Patent #5,766,623 Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

5. Novel Tablets provide 12-16 hours of steady dosage of active compound Novel Tablets provide 12-16 hours of steady dosage of active compound The Description Novel Tablet The tablets consist of: “A chewable tablet made from drug delivery pellets, each drug delivery pellet comprising: a core portion comprising an active agent; and a coating for the core portion, the coating and core portion forming a discrete body, the coating comprising a hydrophilic gel- forming agent undercoating or mixed with a polymeric rate-controlling material”. (U.S. Patent #5,766,623) Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

6. 12 = active agent 20 = hydrophilic gel-forming agent layer 22 = polymeric rate-controlling material layer ***An additional layer (not shown) of binder, disintegrant, and flavor is added over layer 22 The Description Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

7. 12-16 hour relief 12-16 hour relief Chewable, good-tasting tablet Chewable, good-tasting tablet Inexpensive Inexpensive Manufactured with existing equipment Manufactured with existing equipment Patent secured – ready to go Patent secured – ready to go FDA-approved ingredients FDA-approved ingredients Most drug molecules compatible Most drug molecules compatible Few direct competitors Few direct competitors The Benefits Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

8. Licensing is the most time effective, cost effective solution Licensing is the most time effective, cost effective solution First-mover advantage First-mover advantage IP protected via patent IP protected via patent Pharmaceutical drug patent extensions Pharmaceutical drug patent extensions Why License? Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

9. Company interested in R&D investment Company interested in R&D investment Licensee open to innovative ideas Licensee open to innovative ideas Has an entrepreneurial spirit Has an entrepreneurial spirit US roots with worldwide expansion US roots with worldwide expansion Segments in OTC and pharmaceutical markets Segments in OTC and pharmaceutical markets Licensee Criteria Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

10. Exclusive five year license Exclusive five year license Cost of license = $1.5 billion Cost of license = $1.5 billion Royalty fees based on net sales Royalty fees based on net sales Licensee responsible for patent maintenance fees Licensee responsible for patent maintenance fees Net Sales ($US) <$1M9%$4-8M5% $1-2M8%$8-12M4% $2-4M6%>$12M2% The License Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

11. Works with virtually any prescriptive molecule: Works with virtually any prescriptive molecule: Cardiovascular: Cardiovascular: Hypertensives: Coreg Hypertensives: Coreg Respiratory Respiratory Histamines: Advair Histamines: Advair The Opportunity Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

12. 2004Revenue2005Revenue2006Revenue Ave. Growth Projected NT Revenue Coreg$432M$573M$779M+24%+$211M Advair$2,441M$3,003M$3,313M+35%+$1,259M Projections based on: 10% additional premium per tablet 3% additional growth for the following year Implementation of the Novel Tablet delivery system GlaxoSmithKline Financials Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

13. Large over-the-counter market Large over-the-counter market Useful for chronic pain (i.e. back pain, headaches) Useful for chronic pain (i.e. back pain, headaches) No other drug on the market No other drug on the market provides relief this long The Future: Near Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

14. The Future: Near: Issues Novel Tablet Competitors Competitors Consumer adaptability Consumer adaptability Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

15. Drug cocktails Drug cocktails Custom drug combinations Custom drug combinations Infinite possibilities Infinite possibilities The Future: Further Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future

16. Acknowledgements Dr. Jim AyersInventor Dr. Mark ChristensonMentor; College of Pharmacy Ray DandeneauMentor Bill NewmanMentor; Hewlett Packard John TurnerProfessor Oregon State University Novel Tablet Contributors Problem Solution Description Benefits Why License License Details Opportunity Financials Future